Market requirements · SI
Slovenia
JAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropin as usable only on prescription.
| Tell us the compounds you need for Slovenia. | Ask about Slovenia |
The regime
How compounds are classified in Slovenia
| Governing law and regulator | Slovenia's medicines agency is JAZMP (Javna agencija Republike Slovenije za zdravila in medicinske pripomocke). It determines whether a product qualifies as a medicine based on composition, purpose and presentation, independent of how the seller labels it. |
|---|---|
| Direct regulator statement | JAZMP published a notice dated 23 April 2026, 'Opozorilo glede uporabe peptidov za injiciranje' (Warning regarding the use of injectable peptides), after being notified of websites selling injectable peptides with hormone-like, strongly pharmacological effects. |
| Prescription-only compounds named | JAZMP explicitly names semaglutide as an active ingredient usable only on prescription, and somatropin (HGH) as usable only in hospitals under strict medical supervision; products without marketing authorisation have unestablished quality, safety and effectiveness. |
| Function over labelling | JAZMP states legal status is assessed product-by-product: if a product acts on the human body or is presented as changing physiological function, it is treated as a medicine regardless of how it is labelled, directly undercutting any 'research chemical' framing. |
| Enforcement posture | We record JAZMP's public warning as the regulatory action itself; no separate fine or prosecution against a named peptide seller is confirmed, but the warning is dated, primary-source, and the strongest such statement found across all 12 markets. |
| Already supplying Slovenia? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Slovenia needs settled
- Assume JAZMP's function-over-labelling standard is binding: relabelling a compound as 'research use only' does not change its legal status.
- Do not supply semaglutide or somatropin into Slovenia outside licensed prescription or hospital channels.
- Cite JAZMP's 23 April 2026 warning directly in compliance documentation rather than relying on generic EU framing.
- Assume other hormone-like peptides in scope face the same scrutiny even though JAZMP named only semaglutide and somatropin explicitly.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| JAZMP Opozorilo glede uporabe peptidov za injiciranje | 23 April 2026 | www.jazmp.si/2026/04/23/opozorilo-glede-uporabe-peptidov-z... |
| Slovenske novice / Delo Je spletna prodaja peptidov, ki obljubljajo izgubo telesne teze in boljse pocutje, sploh legalna? | not dated in file | slovenskenovice.delo.si/novice/slovenija/je-spletna-prodaj... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Slovenia brief as a PDF
The regime, the buyer obligations and all 2 sources, dated and linked, in one document you can forward.
Nearby
Central and Eastern Europe and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| PL | Poland | 2 sources | GIF and GIS have issued a joint public warning on synthetic peptides offered a... |
| CZ | Czechia | 2 sources | SUKL holds that most synthetic peptides meet the functional definition of a me... |
| SK | Slovakia | 3 sources | SUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press rel... |
| HU | Hungary | 5 sources | OGYEI regulates medicines under Act XCV of 2005. A case-by-case research permi... |
| HR | Croatia | 1 sources | HALMED has published a general rule on online medicine sales. No notice naming... |
| GR | Greece | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific... |
| IE | Ireland | 2 sources | The HPRA detained 763,027 dosage units of falsified or unauthorised medicines ... |
Scope
How to use this page
A summary of the published regulatory position in Slovenia as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Slovenia
Do you supply into Slovenia?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Slovenia depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Slovenia. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Slovenia
Tell us the compounds and your authorisations. We confirm per compound before anything ships.